Company intelligence / Profile preview

Kernel Bio-tech

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Kernel is a Cambridge-based biotechnology company pioneering a programmable mRNA platform designed to enable cell-specific protein expression. Unlike traditional mRNA therapies that express proteins indiscriminately, Kernel's technology uses synthetic biology to create mRNA that only translates in the presence of specific cellular markers. This approach aims to minimize off-target effects and expand the therapeutic window for mRNA in complex diseases like cancer. The company is currently in the pre-clinical stage, focusing on developing a pipeline of next-generation mRNA therapeutics that leverage biological logic gates for precision medicine.

Therapeutic areas: OncologyRare Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Kernel Bio-tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kernel Bio-tech.

Explore the full profile